NL-OMON44987
Completed
Not Applicable
[11C]Erlotinib tumor heterogeneity: an in vivo study using static whole body positron emission tomography in non-small cell lung cancer patients. - [11C]erlotinib tumor heterogeneity in WB PET in patients with NSCLC
Overview
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 30
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational invasive
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •\- Three groups of 10 evaluable patients, i.e. 30 evaluable patients, with histologically proven NSCLC, with an activating EGFR mutation as assessed by HRM and DNA\-sequencing;\- Three groups are:;1\. Patients who were never treated with TKI, planned to receive TKI therapy. ;2\. Patients who relapse under TKI therapy, planned to stop TKI therapy;3\. Patients who relapsed after second line cytotoxic chemotherapy and are planned for TKI retreatment. ;\- Age between 18 and 70 years;\- Life expectancy of at least 12 weeks;\- Malignant lesions (at least 2\) of at least 1\.5 cm diameter as measured by CT ;\- Karnofsky index \>\<\=60%;\- Written informed consent
Exclusion Criteria
- •\- Claustrophobia;\- Pregnant or lactating patients;\- Concurrent treatment with experimental drugs
Investigators
Similar Trials
Completed
Not Applicable
[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission tomography in non-small cell lung cancer patients with and without erlotinib therapy.lung cancernon-small cell lung carcinoma10038666NL-OMON36826Vrije Universiteit Medisch Centrum10
Not yet recruiting
Not Applicable
[11C]Erlotinib in non-small cell lung cancer patients with and without erlotinib therapy.on-small cell lung cancer NSCLCNiet-kleincellig longkankerNL-OMON28948VU University Medical Center10
Completed
Phase 2
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction CancerEsophageal CancerGastric CancerNCT00032123SWOG Cancer Research Network
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
Completed
Phase 1
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)Carcinoma, Non-small Cell LungNCT00729742Merck Sharp & Dohme LLC49